Hybrid Sports Medicine Limited - Limited company accounts 16.3

Hybrid Sports Medicine Limited - Limited company accounts 16.3


IRIS Accounts Production v17.2.0.336 09111140 Board of Directors 1.4.16 31.3.17 31.3.17 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pure091111402016-03-31091111402017-03-31091111402016-04-012017-03-31091111402015-03-31091111402015-04-012016-03-31091111402016-03-3109111140ns15:EnglandWales2016-04-012017-03-3109111140ns14:PoundSterling2016-04-012017-03-3109111140ns10:Director12016-04-012017-03-3109111140ns10:Director22016-04-012017-03-3109111140ns10:PrivateLimitedCompanyLtd2016-04-012017-03-3109111140ns10:SmallEntities2016-04-012017-03-3109111140ns10:AuditExemptWithAccountantsReport2016-04-012017-03-3109111140ns10:SmallCompaniesRegimeForDirectorsReport2016-04-012017-03-3109111140ns10:SmallCompaniesRegimeForAccounts2016-04-012017-03-3109111140ns10:FullAccounts2016-04-012017-03-3109111140ns5:CurrentFinancialInstruments2017-03-3109111140ns5:CurrentFinancialInstruments2016-03-3109111140ns5:ShareCapital2017-03-3109111140ns5:ShareCapital2016-03-3109111140ns5:RetainedEarningsAccumulatedLosses2017-03-3109111140ns5:RetainedEarningsAccumulatedLosses2016-03-3109111140ns5:CurrentFinancialInstrumentsns5:WithinOneYear2017-03-3109111140ns5:CurrentFinancialInstrumentsns5:WithinOneYear2016-03-31


REGISTERED NUMBER: 09111140 (England and Wales)















HYBRID SPORTS MEDICINE LIMITED

REPORT OF THE DIRECTORS AND

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2017






HYBRID SPORTS MEDICINE LIMITED (REGISTERED NUMBER: 09111140)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2017




Page

Report of the Directors 1

Income Statement 2

Balance Sheet 3

Notes to the Financial Statements 4


HYBRID SPORTS MEDICINE LIMITED (REGISTERED NUMBER: 09111140)

REPORT OF THE DIRECTORS
FOR THE YEAR ENDED 31 MARCH 2017

The directors present their report with the financial statements of the company for the year ended 31 March 2017.

PRINCIPAL ACTIVITY
The principal activity of the company in the year under review was that of the provision of private and sports
medical services.

DIRECTORS
The directors shown below have held office during the whole of the period from 1 April 2016 to the date of this
report.

Dr P D Williams
Mrs G E Williams

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2006
relating to small companies.

ON BEHALF OF THE BOARD:





Mrs G E Williams - Director


20 December 2017

HYBRID SPORTS MEDICINE LIMITED (REGISTERED NUMBER: 09111140)

INCOME STATEMENT
FOR THE YEAR ENDED 31 MARCH 2017

2017 2016
Notes £    £   

TURNOVER 58,128 37,496

Cost of sales - 610
GROSS PROFIT 58,128 36,886

Administrative expenses 7,221 3,962
OPERATING PROFIT 50,907 32,924

Interest receivable and similar income 1 -
PROFIT BEFORE TAXATION 50,908 32,924

Tax on profit 10,182 6,585
PROFIT FOR THE FINANCIAL YEAR 40,726 26,339

HYBRID SPORTS MEDICINE LIMITED (REGISTERED NUMBER: 09111140)

BALANCE SHEET
31 MARCH 2017

2017 2016
Notes £    £   
CURRENT ASSETS
Debtors 4 8,857 7,492
Cash at bank 2,167 149
11,024 7,641
CREDITORS
Amounts falling due within one year 5 10,921 7,214
NET CURRENT ASSETS 103 427
TOTAL ASSETS LESS CURRENT
LIABILITIES

103

427

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 3 327
SHAREHOLDERS' FUNDS 103 427

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2017.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2017 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the
Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at
the end of each financial year and of its profit or loss for each financial year in accordance with the
requirements of Sections 394 and 395 and which otherwise comply with the requirements of the
Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the Board of Directors on 20 December 2017 and were signed on
its behalf by:





Dr P D Williams - Director


HYBRID SPORTS MEDICINE LIMITED (REGISTERED NUMBER: 09111140)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2017

1. STATUTORY INFORMATION

Hybrid Sports Medicine Limited is a private company limited by shares, registered in England & Wales.
The company's registered office is situated at 108 Stanwell Road, Penarth, Cardiff,CF64 3LP. The
company's registered number is shown on the front page of the Financial Statements

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The financial statements have been prepared under the historical cost basis of accounting.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 .

4. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2017 2016
£    £   
Trade debtors 8,857 7,492

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2017 2016
£    £   
Trade creditors 1 -
Taxation and social security 10,182 6,586
Other creditors 738 628
10,921 7,214

6. RELATED PARTY DISCLOSURES

Monies were owed to the directors at the end of the period amounting to £13 (2016 £28) The
balances are included within creditors payable in under one year.
The company is under the control of the directors who own 100% of the issued share capital.